3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
3
Recurrence
2
Melanoma
2
Lymphoma, Large B-Cell, Diffuse
2
Hodgkin Disease
2
Various Advanced Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Liver Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Gastroesophageal Cancer
1
Fallopian Tube Neoplasms
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Advanced Cancer
1
Interventions
Cyclophosphamide
5
Brentuximab Vedotin
5
Vincristine
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Ifosfamide
4
Etoposide
4
Doxorubicin
4
Carboplatin
4
romidepsin
3
fludarabine phosphate
3
brigatinib
3
Prednisone
3
Lenalidomide
3
Everolimus
3
10-propargyl-10-deazaaminopterin
3
pembrolizumab
2
indolepropanol phosphate
2
Whole-Body Irradiation
2
Vorinostat
2
Mycophenolic Acid
2
Microarray Analysis
2
Immunohistochemistry
2
Gene Expression Profiling
2
Cytarabine
2
Cyclosporine
2
Clofarabine
2
Bendamustine Hydrochloride
2
veliparib
1
repotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Large-Cell, Anaplastic
×
relatlimab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled